News Provided by Digbi Health
July 22 2024 10:00 EST
State Public Health Insurance Trust Partners with Digbi Health to Manage Obesity Treatment Costs Amid Rising GLP-1 Drug Expenses for its Municipal and Teachers Union Workers
Mountain View, July 22, 2024 – A leading public health insurance trust has selected Digbi Health to manage the escalating costs and effective utilization of new GLP-1 weight-loss drugs. This partnership will leverage Digbi Health's proprietary Obesity Compass to provide effective and cost-efficient treatment plans for all its members.
Due to the surge in demand for GLP-1 drugs, employers and health plans nationwide face uncertainty and significant cost increases. This partnership addresses these challenges by employing innovative solutions without compromising a member’s health.
Key Highlights:
- Effective Cost Management:The initiative launched in June as a cost-containment strategy after unsustainable growth in GLP-1 medication usage and costs.
- Prior Authorization:Digbi Health will oversee the Prior Authorization for all weight management medications, using patented predictive modeling to determine the most effective and economical care modalities for members to achieve a healthy BMI.
- Holistic Solution: Digbi Health leverages genetics, gut microbiome, continuous glucose monitoring (CGM), and lab reports to provide personalized food and lifestyle support to all members on weight management medications. This approach addresses the underlying root causes of their conditions, related comorbidities, medication side effects, and, if recommended, medication tapering.
Precision Biology is an innovative approach that uses an individual's genetic makeup, gut microbiome profile, and metabolic data to create highly personalized treatment plans. Precision Biology can identify the most effective dietary, lifestyle, and pharmacological interventions by analyzing a person's unique biological data. This method ensures that treatments are tailored to address the root causes of obesity and related conditions, resulting in more effective and sustainable health outcomes.
“As the market struggles with finding an optimal strategy for weight management and GLP-1 cost containment, we aim to set new care standards by focusing on three key areas: enhancing member experiences through integrations, using Precision Biology to more accurately identify those who need medication support, and tackling the underlying root causes, comorbidities, and side effects.
We look forward to successfully collaborating with employers, health plans, benefits consultants, and PBMs to deliver personalized, effective, and affordable care,” said Ranjan Sinha, Founder and CEO of Digbi Health.
About Digbi Health:
Digbi Health pioneered Precision Biology to treat obesity, T2 Diabetes, and digestive health by harnessing genetics and gut microbiome analysis. This innovative approach develops personalized "Food-As-Medicine" treatment plans, targeting the root causes of obesity and T2D. Digbi Health’s GLP Compass, developed working with Novo Nordisk and the University of Virginia Medical School, uses proprietary data and AI models to identify the most clinically effective and cost-efficient treatment paths.
